CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 1. Effects of bryostatin-1 and GM-CSF on AML cell line clonogenic growth. U937 (A) and HL60 (B) cells were incubated in the absence (Control) or presence of bryostatin-1 (10-8 M) with or without GM-CSF (200 units/ml). Results represent the percentage of clonogenic recovery compared with untreated control samples and are the means of five separate experiments; bars, SE. P < 0.001 was accessed by ANOVA for the comparison of the treatment groups in both the U937 (A) and HL60 (B) cells.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation